We report herein the design and synthesis of a series of structural modified dimethylpyridazine compounds as novel hedgehog signaling pathway inhibitors. The bicyclic phthalazine core and 4-methylamino-piperidine moiety of Taladegib were replaced with dimethylpyridazine and different azacycle building blocks, respectively. The in vitro Gli-luciferase assay results demonstrate that the new scaffold still retained potent inhibitory potency. Piperidin-4-amine moiety was found to be the best linker between pharmacophores dimethylpyridazine and fluorine substituted benzoyl group. Furthermore, the optimization of 1-methyl-1H-pyrazol and 4-fluoro-2-(trifluoromethyl)benzamide by different aliphatic or aromatic rings were also investigated and the SAR were described. Several new derivatives were found to show potent Hh signaling inhibitory activity with nanomolar IC values. Among these compounds, compound 11c showed the highest inhibitory potency with an IC value of 2.33 nM, which was comparable to the lead compound Taladegib. In vivo efficacy of 11c in a ptchp53 mouse medulloblastoma allograft model also indicated encouraging results.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bmc.2018.04.058 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!